Lin Xu, MD
Psychiatry · Wichita, KSNPI 1184675712
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 554 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,090 and has fallen 81.8% since, to $380 in 2025.
Across 554 payments — averaging $15.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- Johnson & Johnson$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Alkermes, Inc.$930
- Vanda Pharmaceuticals Inc.$797
- AbbVie$720
- plus $3K from 18 others
What the payments were for
- Food & beverage$8,813100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 89 | $1,370 |
| Johnson & Johnson | 63 | $1,059 |
| Teva Pharmaceuticals USA, Inc. | 50 | $1,035 |
| Alkermes, Inc. | 48 | $930 |
| Vanda Pharmaceuticals Inc. | 38 | $797 |
| AbbVie(2 entities) | 49 | $720 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 41 | $644 |
| Lundbeck LLC | 40 | $543 |
| Neurocrine Biosciences, Inc. | 46 | $421 |
| Sunovion Pharmaceuticals Inc. | 34 | $419 |
| Indivior Inc. | 22 | $298 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $226 |
| Merck | 6 | $87 |
| Eisai Inc. | 2 | $56 |
| Shire North American Group Inc | 3 | $40 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Noven Therapeutics, LLC | 1 | $25 |
| Biogen | 1 | $24 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
| Bausch Health US, LLC | 1 | $12 |
| Tris Pharma Inc | 1 | $11 |
| Avanir Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$400
- INVEGA SUSTENNA$224
- AUSTEDO$131
- SPRAVATO$105
How this compares
$8,813 in reported general payments places this provider in the 85th percentile of 259 psychiatry providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 151 | $467,724 |
| Invega TrinzaPaliperidone Palmitate | 18 | $160,732 |
| Abilify MaintenaAripiprazole | 59 | $148,719 |
| VraylarCariprazine Hcl | 71 | $102,559 |
| PerserisRisperidone | 21 | $57,688 |
| AristadaAripiprazole Lauroxil | 17 | $46,196 |
| RexultiBrexpiprazole | 34 | $45,942 |
| TrintellixVortioxetine Hydrobromide | 53 | $25,296 |
| Risperdal ConstaRisperidone Microspheres | 27 | $25,035 |
| Clozapine | 324 | $17,813 |
| FetzimaLevomilnacipran Hcl | 24 | $13,196 |
| Divalproex Sodium ErDivalproex Sodium | 112 | $5,041 |
| Paliperidone ErPaliperidone | 52 | $4,503 |
| Fluphenazine Hcl | 72 | $4,245 |
| Fluphenazine Decanoate | 36 | $3,739 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta | $1,059 | $653,491196 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,370 | $194,66193 claims |
| AbbVieVraylar, Fetzima | $720 | $115,75595 claims |
| Indivior Inc.Perseris | $298 | $57,68821 claims |
| Alkermes, Inc.Aristada | $930 | $46,19617 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $226 | $25,29653 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 259 psychiatry providers in Kansas.
Other psychiatry in Wichita
- Sheldon PreskornWichita$498K
- Heidi OgdenWichita$55K
- Ralph BharatiWichita$26K
- Paul MurphyWichita$19K
- Dwight St ClairWichita$18K
- Mukhtar ShahWichita$12K
- Rex LearWichita$11K
- Mercedes PeralesWichita$8K
- Jasmine KaurWichita$6K
- Peter SeilerWichita$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.